Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin

Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose cotransporter 2 (SGLT2) inhibitors are an emerging class of an...

Full description

Bibliographic Details
Main Author: Andrew Ahmann
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2015-11-01
Series:Drugs in Context
Subjects:
type 2 diabetes mellitus
sodium glucose cotransporter 2
empagliflozin
blood glucose
body weight
insulin
combination therapy
hypoglycemic agents
Online Access:http://www.drugsincontext.com/combination-therapy-in-type-2-diabetes-mellitus-adding-empagliflozin-to-basal-insulin/

Internet

http://www.drugsincontext.com/combination-therapy-in-type-2-diabetes-mellitus-adding-empagliflozin-to-basal-insulin/

Similar Items